Trial Profile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NBI-1117570 (Primary)
Indications Schizophrenia
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Neurocrine Biosciences

Most Recent Events

02 Jun 2025 Status changed from recruiting to discontinued, on Sponsor Decision.
14 Jan 2025 According to a Nxera Pharma Co., Ltd. media release, the company anticipates receiving data readouts in 2025.
01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com